UnitedHealth Group Incorporated (NYSE:UNH) is included among the 15 Best S&P 500 Stocks to Buy Right Now.
UnitedHealth Group Incorporated (NYSE:UNH) is a health care and well-being company with team members in two distinct and complementary businesses – its insurance wing, UnitedHealthcare, and its health services segment, Optum.
UnitedHealth Group Incorporated (NYSE:UNH) received a boost on April 1 when Raymond James analyst John Ransom upgraded the stock from ‘Market Perform’ to ‘Outperform’. The analyst assigned UNH a price target of $330, indicating an upside of 19% from the current levels.
Mr. Ransom cited a potential upside to the company’s earnings estimates over the coming years for the upgrade. The analyst expects a ‘modest’ 20 basis point upside to UnitedHealth Group Incorporated (NYSE:UNH)’s general and administrative expenses for 2027 and 2028, driven by potential AI initiatives and margin improvement at the company’s health services arm, Optum Health.
UnitedHealth Group Incorporated (NYSE:UNH) is projecting cost reductions of nearly $1 billion for FY 2026, largely attributed to AI and automation. The company expects an adjusted EPS of greater than $17.75 for the year, with measured growth across all reporting segments, and UnitedHealthcare is projected to deliver double-digit improvements. The Minnesota-based firm has a revenue guidance of nearly $440 billion for 2026.
Mairs & Power, an investment advisor, recently stated the following regarding UnitedHealth Group Incorporated (NYSE:UNH) in its Q4 2025 investor letter:
“While stock selection has historically delivered positive long-term results for our shareholders, it was a notable headwind in 2025, with Fiserv (FI) and UnitedHealth Group Incorporated (NYSE:UNH) standing out as prominent detractors from relative performance. Despite their recent pullbacks, both positions remain substantial long-term winners, appreciating more than 300% and 100%, respectively, since our initial investments.
Both companies experienced significant execution missteps that ultimately resulted in weaker-than-expected reported fundamentals. Although we had been trimming these positions due to stretched valuations and growing concerns around leadership uncertainty, in hindsight we should have acted more decisively in reducing our exposure to these names.
That said, we believe the challenges at both companies are largely self-inflicted operational issues rather than structural impairments to their franchises. In short, the problems appear fixable but will take time to resolve. We are therefore comfortable maintaining our current positions and believe patient capital will ultimately be rewarded as execution improves…” (Click here to read the full text)